By 2035, for every $1 the Philippines will spend in treating hepatitis, hepatocellular carcinoma (HCC), nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) and cirrhosis, the country will receive $2.23 in return, according to the Asia Pacific (APAC) Liver Disease Alliance. “Despite the large investment needed in treating HCC and other liver-related diseases,…